3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
31
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleuropulmonary blastoma
1
Pathologic Complete Response
1
Neurofibrosarcoma
1
Neuroblastoma
1
Interventions
Control Groups
2
Atorvastatin
2
sacubitril and valsartan sodium hydrate drug combination
1
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
dapagliflozin
1
candesartan
1
Trastuzumab
1
Sodium Chloride
1
Simendan
1
Pyruvic Acid
1
Population Groups
1
Ogivri
1
Metoprolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Eplerenone
1
Carvedilol
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Heart Failure
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled